ClearTract® Foley Catheters

There are now an estimated 1 million catheter-associated urinary tract infection (CAUTI) cases per year in the United States costing an estimated $13,793 per case

Testimonials

“Silq Technologies is bringing a game changing innovation to the care of patients who require catheters for bladder drainage.”

Evgeniy Kreydin, M.D. Clinical Urology, Keck Hospital of University of Southern California

“I was immediately impressed with the difference with this catheter…I do not have pain when catheter is changed. I do not think I would go back to the other catheters ever again.”

Ana Garcia | Silq ClearTract Patient (July 2023)

“This has been like a miracle for us and we are unbelievably grateful for Brian McVerry and the SILQ Corporation for this incredible breakthrough.”

Stephen and Dolores Newhouse | Parents of a Silq ClearTract Patient

"I have said it more than once, but I won’t use any other catheter out there... I have spoken to other Silq users and they feel the same way I do.”

Dulce Garcia | Silq ClearTract Patient (July 2023)

The Benefits of ClearTract®

Silq’s groudbreaking surface technology has been shown to be able to reduce the adhesion of pathogenic microbes without the use of antibiotics.

Our ClearTract Catheters are made from 100% medical grade silicone with no latex, BPA, or DEHP and demonstrate dramatically reduced endotoxin levels compared to other catheters on the market

  • Silq-treated devices meet the most rigorous requirements for biocompatibility testing

  • Silq ClearTract products are designed to stop infections before they even begin, without the need for antibiotic drugs

  • Silq Treatment has been shown to improve the lubricity of medical grade silicones by up to 18X, alleviating patient discomfort during the implant and explant

  • Unlike catheters made with latex, ClearTract catheters meet the FDA's nonpyrogenicity criteria for blood contacting devices.

*Data on file available by request

Overuse of Antibiotic Drugs: A growing concern

According to the WHO, is is estimated that bacterial antimicrobial resistance was directly responsible for 1.27 million deaths in 2019 and scientists project this number to grow to 10 million by 2050. This resistance is primarily driven by the misuse and overuse of antibiotic drugs.

In 2022 the CDC published findings that COVID-19 pandemic had severely worsened the problem of antimicrobial resistance. A July 2024 update to the report stated, “Additional action is critical. We can and must do more to combat antimicrobial resistance”

ClearTract Catheters using Silq’s platform technology represent a new type of solution in the fight against infections. By not seeking to kill bacterial cells and instead simply preventing colonization of the catheter surface, our goal is to stop infections before they even begin and prevent the need for antibiotic drugs.

Contact us or download our brochure to learn more